Post-Hoc Live: How much is everyone in biopharma getting paid?

The one law of CEO pay packages: They keep getting bigger. Yesterday, we published the first installment of Endpoints News’ annual biopharma compensation project. Following our analysis of the industry’stop-paid CEOs, we’ll break down what top science and medical leaders make, dig intomedian employee pay(and how that compares to CEOs) and unveil the richest golden parachutes, as well as an examination of executive perks.

You’ll be able to find all of that reportinghere. Today on Post-Hoc Live, I joinedExecutive Editor Drew Armstrongto dig into the eye-popping numbers in some CEO pay packages and the behind-the-scenes of how this reporting comes together. Putting all this data together in one place does more than just reveal biopharma’s payroll.

It also raises questions about how these companies think about leadership and prioritize their budgets. Are there other ways biopharmas could spend some of the millions going toward executive packages? Do CEOs actually get paid commensurate with their company’s success?

How does pay affect incentives and global competition? You can watch a replay of the show onYouTube. Thanks for watching and listening!

— Andrew Dunn, Senior Biopharma CorrespondentAUTHORAndrew DunnSenior Biopharma [email protected] Think we're worth reading - tell Google. Confirm Endpoints as a trusted biopharma news source Vice President, Regulatory Affairs FDA adcomm votes in favor of benefit-risk of Grail’s cancer test In a changed world for cystic fibrosis, a family's fight reveals a new gap in care Roche kidney drug's Phase 3 win sets up path to accelerated approval Chinese vaccine scandal leads to life sentence; Flagship wins defense contract Baby KJ's gene-editing drug cost $1.65M to make, Fyodor Urnov says Everybody optimizes the first 20% of patient recruitment. Trials fall apart in the other 80%.

Reports indicate that the one law of CEO pay packages: They keep getting bigger. Yesterday, we published the